Plain-English translation of NCT07073950 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a new inhaler called (BGF) to see how it affects both your heart and lung function in people with COPD and hyperinflation—a condition where your lungs trap too much air. The medication combines three active ingredients designed to open your airways and reduce inflammation. Researchers want to make sure this treatment is safe and works well for your heart as well as your lungs.
People with COPD often struggle with air trapping in their lungs, which makes breathing harder and can affect heart function. This study exists to understand whether this new combination treatment can safely improve both lung and heart health, and to make sure it doesn't cause any unexpected heart problems.
You likely qualify if…
You likely don't qualify if…
You will visit the study center multiple times over several weeks. First, you'll go through a screening period where researchers check if you qualify. Then you'll enter two treatment periods lasting 21 days each—in one period you'll use the new inhaler, and in the other you'll use a placebo (dummy) inhaler, though neither you nor the researchers will know which is which. Between and after these periods, you'll have follow-up visits where doctors will test your heart and lung function using standard breathing tests and heart monitoring.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Germany
United Kingdom